Abeona therapeutics announces database lock for pivotal phase 3 viital™ study of eb-101 in patients with recessive dystrophic epidermolysis bullosa (rdeb)

New york and cleveland, oct. 19, 2022 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced the database lock on october 18, 2022 for the pivotal phase 3 viital™ study of its investigational autologous, engineered cell therapy, eb-101, in patients with recessive dystrophic epidermolysis bullosa (rdeb). with the database now locked, the company remains on track to report topline results in the next two to three weeks, consistent with guidance provided in early-october.
ABEO Ratings Summary
ABEO Quant Ranking